Key facts
- Novaken Pharm’s last known valuation is $215.1M (Nov 2025).
- It has raised $39.1M; the latest was IPO in Dec 2025.
- Notable investors include Zhuhai Gree Financial Investment, ZJVC Venture Capital, Taiyou Fund, Lianyungang Jinhai Venture Capital, Guangzhou Guangyao Capital — 9 tracked in total.
- Status: In IPO Registration.
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for Novaken Pharm
- ·The full record, as it builds
Funding rounds
No funding rounds for Novaken Pharm are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Novaken Pharm
Manufacturer of medicines and health products intended to control drug release, sustained release and targeted drug release. The company's pharmaceutical preparations focus on new drug formulations and drug delivery systems, enabling patient to recover from disease.
- Sector
- Business Products and Services (B2B)
- HQ
- Guangzhou, China
- Founded
- 2007
- Employees
- 185
- Website
- novaken.cn/
- Ownership
- In IPO Registration
Novaken Pharm doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Novaken Pharm shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Novaken Pharm in its N-PORT filings yet. We sweep new filings monthly.